Elm Street Ventures

Elm Street Ventures is a venture capital firm based in New Haven, Connecticut, that specializes in early-stage investments in life sciences and technology companies. The firm focuses on companies founded on intellectual property developed at Yale University and other regional research institutions, spanning from New York City to Southern New England. In the life sciences sector, Elm Street Ventures invests in therapeutics, medical devices, diagnostics, and healthcare services, while in technology, it targets software, clean technology, and information technology, among others. The firm typically makes initial investments ranging from several hundred thousand dollars to over $1 million, often participating in syndicates with other institutional investors. With a team that includes experienced entrepreneurs and corporate managers, Elm Street Ventures aims to support scientists and engineers in building significant technology companies at the seed and early stages.

Rob Bettigole

Founder and Managing Partner

Rick Stahl

Venture Partner

Michael Sherman Ph.D

Partner

24 past transactions

Allyx Therapeutics

Venture Round in 2021
Allyx Therapeutics, founded in 2018 and located in Durham, Connecticut, is a clinical-stage biotechnology company focused on developing disease-modifying treatments for Alzheimer's Disease. The company specializes in a therapeutic drug that is an orally bioavailable small molecule, functioning as a silent allosteric modulator of mGluR5. This innovative approach aims to reverse neurodegeneration and preserve cognitive function in patients, offering a potential breakthrough in Alzheimer's treatment.

Cybrexa, Inc.

Series B in 2021
Cybrexa, Inc. develops DNA repair inhibitors for radio- and chemo-sensitizers in cancer therapeutics. The product consists of peptide-based technology that directly targets tumor microenvironment. Cybrexa, Inc. was formerly known as Cybrexa, Inc. The company was founded in 2016 and is based in New Haven, Connecticut.

Artizan Biosciences

Series A in 2021
Artizan Biosciences develops small molecule drugs targeting human diseases, utilizing its IgA-SEQ technology platform to identify disease-driving bacteria within the intestinal microbiota. Founded in 2016 and headquartered in New Haven, Connecticut, the company focuses on creating new and potentially curative treatments. With a commitment to advancing pharmaceutical drug development, Artizan Biosciences aims to address unmet medical needs through innovative approaches in biotechnology.

P2 Science

Series C in 2020
P2 Science, Inc. is a bio-renewable chemistry company based in Woodbridge, Connecticut, specializing in the development and production of specialty chemicals derived from renewable feedstocks, such as vegetable oils. Founded in 2009 by a team that includes Yale scientists and an experienced chemical industry executive, the company focuses on creating high-value ingredients for flavors, fragrances, cosmetics, and other applications. P2 Science aims to provide sustainable alternatives to traditional petrochemical products, catering to diverse markets, including personal care, household cleaning, agriculture, and environmental remediation. Their innovative technology enables the conversion of renewable resources into cost-effective chemical solutions, addressing the increasing demand for greener options among major users in the specialty chemicals sector. The company also maintains a laboratory in New Haven, Connecticut, to support ongoing research and partnerships throughout the supply chain.

EvolveImmune Therapeutics

Venture Round in 2020
EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generate first-in-class treatments for unmet needs in oncology and autoimmune diseases.

Zid

Seed Round in 2019
Zid is a cloud-based multi-channel commerce platform tailored for small and medium-sized businesses in Saudi Arabia. Founded in 2017 and headquartered in Riyadh, Zid enables merchants to create their own branded eStores while integrating with various supply chain players. The platform offers a comprehensive suite of tools that allow users to manage products and inventory, process orders and payments, ship products, and build customer relationships. It also provides analytics and reporting features, facilitating data-driven decision-making, and offers access to financing options. Zid's mission is to simplify the entry of retailers into electronic commerce, making it accessible and professional for businesses in the region.

Artizan Biosciences

Series A in 2019
Artizan Biosciences develops small molecule drugs targeting human diseases, utilizing its IgA-SEQ technology platform to identify disease-driving bacteria within the intestinal microbiota. Founded in 2016 and headquartered in New Haven, Connecticut, the company focuses on creating new and potentially curative treatments. With a commitment to advancing pharmaceutical drug development, Artizan Biosciences aims to address unmet medical needs through innovative approaches in biotechnology.

Halda Therapeutics

Series A in 2019
Halda Therapeutics is a research-stage drug discovery company, seeking to create the next generation of precision medicine based on a novel therapeutic modality which may be a platform for a number of disease states.

Iconic Therapeutics

Venture Round in 2018
Iconic Therapeutics, Inc. operates as a biopharmaceutical company that translates tissue factor biology in angiogenesis, inflammation, and metastasis to develop new therapeutics for retinal disease and cancer. Its products include ICON-1, a fusion protein designed to address the basis of vision loss in age-related macular degeneration. Iconic Therapeutics, Inc. was incorporated in 2002 and is based in South San Francisco, California.

Saphlux

Series A in 2017
Saphlux, Inc. develops, produces, and commercializes semi-polar gallium nitride (GaN) materials that solve droop and green gap problems in LEDs and lasers. The company offers semi-polar GaN templates in two diameters or customized size (quarters). Saphlux, Inc. was founded in 2014 and is based in New Haven, Connecticut.

P2 Science

Series B in 2017
P2 Science, Inc. is a bio-renewable chemistry company based in Woodbridge, Connecticut, specializing in the development and production of specialty chemicals derived from renewable feedstocks, such as vegetable oils. Founded in 2009 by a team that includes Yale scientists and an experienced chemical industry executive, the company focuses on creating high-value ingredients for flavors, fragrances, cosmetics, and other applications. P2 Science aims to provide sustainable alternatives to traditional petrochemical products, catering to diverse markets, including personal care, household cleaning, agriculture, and environmental remediation. Their innovative technology enables the conversion of renewable resources into cost-effective chemical solutions, addressing the increasing demand for greener options among major users in the specialty chemicals sector. The company also maintains a laboratory in New Haven, Connecticut, to support ongoing research and partnerships throughout the supply chain.

SeeClickFix

Venture Round in 2015
SeeClickFix, Inc. is a communications platform designed to facilitate reporting of non-emergency issues by citizens and to enable governments to manage and respond effectively. Founded in 2007 and headquartered in New Haven, Connecticut, the company provides several tools aimed at enhancing civic engagement and government transparency. Its offerings include Request Management for gathering data and tracking work orders, Work Management for optimizing internal communication and assignments, and Citizen Engagement tools to inform and involve local communities. Additionally, SeeClickFix provides analytics tools that help assess public service performance and guide decision-making. The platform caters to various sizes and budgets, empowering residents, community organizations, and government officials to collaboratively enhance their neighborhoods. SeeClickFix operates as a subsidiary of CivicPlus, LLC.

P2 Science

Series A in 2014
P2 Science, Inc. is a bio-renewable chemistry company based in Woodbridge, Connecticut, specializing in the development and production of specialty chemicals derived from renewable feedstocks, such as vegetable oils. Founded in 2009 by a team that includes Yale scientists and an experienced chemical industry executive, the company focuses on creating high-value ingredients for flavors, fragrances, cosmetics, and other applications. P2 Science aims to provide sustainable alternatives to traditional petrochemical products, catering to diverse markets, including personal care, household cleaning, agriculture, and environmental remediation. Their innovative technology enables the conversion of renewable resources into cost-effective chemical solutions, addressing the increasing demand for greener options among major users in the specialty chemicals sector. The company also maintains a laboratory in New Haven, Connecticut, to support ongoing research and partnerships throughout the supply chain.

Arvinas

Series A in 2013
Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. The company was founded in 2013 and is headquartered in Connecticut, United States.

P2 Science

Seed Round in 2013
P2 Science, Inc. is a bio-renewable chemistry company based in Woodbridge, Connecticut, specializing in the development and production of specialty chemicals derived from renewable feedstocks, such as vegetable oils. Founded in 2009 by a team that includes Yale scientists and an experienced chemical industry executive, the company focuses on creating high-value ingredients for flavors, fragrances, cosmetics, and other applications. P2 Science aims to provide sustainable alternatives to traditional petrochemical products, catering to diverse markets, including personal care, household cleaning, agriculture, and environmental remediation. Their innovative technology enables the conversion of renewable resources into cost-effective chemical solutions, addressing the increasing demand for greener options among major users in the specialty chemicals sector. The company also maintains a laboratory in New Haven, Connecticut, to support ongoing research and partnerships throughout the supply chain.

Desmos

Venture Round in 2012
Desmos, Inc. is a San Francisco-based company that specializes in developing a web-based graphing calculator designed for students and teachers both in the United States and internationally. Founded in 2007 and originally known as Tutor Trove, LLC, Desmos offers a platform that enables users to graph functions, plot tables of data, evaluate equations, and explore mathematical transformations. The company's software is notable for being platform-agnostic, allowing for the creation and sharing of rich educational content that connects classrooms and extends learning beyond the school environment.
Accelerated Orthopedic Technologies, Inc., based in Guilford, Connecticut, specializes in developing proprietary instruments designed to treat articular cartilage defects. The company offers custom-sized tools that match the topography required for effective cartilage grafting. Founded in 2009 and originally known as Advanced Orthopedic Technologies, the company rebranded in February 2010. Its innovative approach aims to improve outcomes in orthopedic procedures by providing tailored solutions for cartilage repair.

Metagenomix

Seed Round in 2010
Metagenomix is an early-stage biotechnology company developing novel methods of screening microbes for pharmacologically active compounds. Among the indications under investigation are cancer, inflammation and infectious diseases including fungal infections and malaria. The technology also has applications in agriculture.

Kolltan Pharmaceuticals

Series A in 2009
Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company founded in 2007 and based in New Haven, Connecticut. The company focuses on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. Its lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK, currently undergoing Phase I clinical trials for advanced solid tumors. Additionally, Kolltan is developing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory conditions, as well as an antibody-drug conjugate known as KIT-ADC for oncology applications. The company also engages in various research programs targeting RTKs, building on foundational discoveries made in collaboration with Dr. Joseph Schlessinger's laboratory at Yale University, which elucidate the molecular mechanisms linked to RTK activation and oncogenic mutations.

Iconic Therapeutics

Venture Round in 2009
Iconic Therapeutics, Inc. operates as a biopharmaceutical company that translates tissue factor biology in angiogenesis, inflammation, and metastasis to develop new therapeutics for retinal disease and cancer. Its products include ICON-1, a fusion protein designed to address the basis of vision loss in age-related macular degeneration. Iconic Therapeutics, Inc. was incorporated in 2002 and is based in South San Francisco, California.

ShareGrove

Seed Round in 2009
ShareGrove hosts private online conversations that are media-rich, fluid and dynamic. ShareGrove makes it easy to select friends from Facebook (and other networks), and to engage them in real time, or over time, through a single Web interface. Integrated Web search (from Google, Amazon and Yelp), along with inline presentation of media, add richness and expression to ShareGrove conversations, while also generating revenues through affiliate programs.

Retail Optimization

Series B in 2008
Retail Optimization Inc. specializes in predictive macro optimization analytics aimed at improving profitability in retail environments. The company offers solutions for space management, store remodeling, and assortment planning, enabling retailers and suppliers to identify optimal product selection, category space, and inventory investment. Their software integrates various elements, including consumer insights, supply chain dynamics, market data, and store layouts, to enhance the overall shopping experience for consumers. By leveraging these analytics, retailers can make informed decisions about category, aisle, department, and store size, ultimately driving efficiency and effectiveness in their operations.

Affomix

Series A in 2008
Affomix is a biotechnology company specializing in the development of antibody-based products. Utilizing proprietary technology, it offers rapid and automated high-throughput selection of human monoclonal antibodies (mAbs). The company focuses on commercializing its mAbs, along with mAb microarrays and mAb libraries, for various applications in research, drug discovery, diagnostics, and therapeutics. Affomix aims to enhance the sensitivity and accuracy in measuring large numbers of proteins in biological samples, leveraging its capabilities to produce and screen antibodies against virtually all human proteins, including those that are post-translationally modified.

BioRelix

Series A in 2007
BioRelix, Inc., a biopharmaceutical company, engages in the discovery and development of anti-biotic drug candidates for the treatment of infectious diseases in the United States. It develops a portfolio of riboswitch-based therapeutic agents to overcome the lethal and devastating causes of bacterial infections. The company was founded in 2005 and is based in New Haven, Connecticut.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.